Therapeutics News and Research

RSS

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

Pain Therapeutics third quarter net loss decreases from $1.3 million to $1.0 million

Pain Therapeutics, Inc. a biopharmaceutical company, today reported financial results for its third quarter of fiscal year 2010.

29 Oct 2010

Pro-Pharmaceuticals ships first commercial order of DAVANAT to PROCAPS in Colombia

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has shipped its first commercial order of DAVANAT® to PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. The $200,000 shipment of DAVANAT® will be used by PROCAPS to qualify its vial filling process.

28 Oct 2010

New nationwide initiative to conduct research on human immune system

A new nationwide research initiative has been launched to define changes in the human immune system's response to infection and vaccination using human rather than animal models, which could lead to better vaccines and other treatments. Baylor Research Institute (BRI), along with five other U.S.-based Human Immune Phenotyping Centers, will receive a total of $100 million over five years to conduct the research.

28 Oct 2010

United Therapeutics third quarter total revenues increase to $171.0 million

United Therapeutics Corporation today announced its results of operations for the quarter ended September 30, 2010.

28 Oct 2010

Pancreatic cancer develops and spreads more slowly than thought before

Pancreatic cancer develops and spreads much more slowly than scientists have thought, according to new research from Johns Hopkins investigators. The finding indicates that there is a potentially broad window for diagnosis and prevention of the disease.

28 Oct 2010

Immune system may play a role in cancer therapies: Study

The immune system may play a critical role in ensuring the success of certain types of cancer therapies, according to a new study by researchers at the Stanford University School of Medicine. The research showed treatments that disable cancer-promoting genes called oncogenes are much more successful in eradicating tumors in the presence of a signaling molecule secreted by kind of immune cell called a T helper cell.

28 Oct 2010

Cell Therapeutics 2010 third quarter total net operating expense decreases 52% to $13.0 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the third quarter ended September 30, 2010.

28 Oct 2010

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

28 Oct 2010

InVivo Therapeutics completes reverse merger with InVivo

InVivo Therapeutics Corporation a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced the successful completion of a reverse merger with InVivo Therapeutics Holdings Corp.

28 Oct 2010

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).

27 Oct 2010

Scripps Florida scientist receives grant from Landenberger Foundation for HIV research

A scientist on the Florida campus of The Scripps Research Institute has received funding from the Philadelphia-based Margaret Q. Landenberger Research Foundation.

27 Oct 2010

New International malaria research consortium to develop novel classes of antimalarials

Research teams from three academic institutions and two private sector companies on two continents have come together to form the International malaria research consortium for the development of novel classes of antimalarials. This bold initiative will develop novel classes of drugs against malaria, a deadly disease in desperate need of new treatments.

27 Oct 2010

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan Corporation, plc today reported its third quarter and first nine months 2010 financial results.

27 Oct 2010

New Australian start-up venture could lead to a revolution in personalized medicine

Pharmaceuticals that seek out cancerous cells and deliver treatments to them; imaging techniques that can help doctors detect diseases before the physical signs begin to appear; and medicines that are tailor-made for individual patients, are within the sights of an exciting new Australian start-up venture.

27 Oct 2010

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.

27 Oct 2010

Boehringer Ingelheim and MacroGenics enter global antibody-based therapeutics alliance

Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases.

27 Oct 2010

AutoGenomics granted FDA 510(k) clearance for INFINITI CYP2C19 Assay

AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its INFINITI® CYP2C19 Assay. The test detects 3 genetic variants, *2, *3, *17, of the CYP450 2C19 gene and is to be used on the company's automated molecular testing platform, the INFINITI® Analyzer.

27 Oct 2010

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

Infinity Pharmaceuticals, Inc. today announced that Purdue Pharmaceutical Products L.P. and its independent associated company, Mundipharma International Corporation Ltd., have exercised their right to assume worldwide development and commercialization activities for Infinity's fatty acid amide hydrolase, or FAAH, program. The decision reflects progress made in the development of Infinity's oral FAAH inhibitor, IPI-940.

26 Oct 2010

miRagen and CU enter agreement on miRNA therapeutics discovery and development

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and the University of Colorado (CU) announced today that they have entered into sponsored research and licensing agreements to collaborate on miRNA therapeutics discovery and development.

26 Oct 2010

Therapeutics News and Research

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Pain Therapeutics third quarter net loss decreases from $1.3 million to $1.0 million

Pro-Pharmaceuticals ships first commercial order of DAVANAT to PROCAPS in Colombia

New nationwide initiative to conduct research on human immune system

United Therapeutics third quarter total revenues increase to $171.0 million

Pancreatic cancer develops and spreads more slowly than thought before

Immune system may play a role in cancer therapies: Study

Cell Therapeutics 2010 third quarter total net operating expense decreases 52% to $13.0 million

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

InVivo Therapeutics completes reverse merger with InVivo

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

Scripps Florida scientist receives grant from Landenberger Foundation for HIV research

New International malaria research consortium to develop novel classes of antimalarials

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

New Australian start-up venture could lead to a revolution in personalized medicine

MacroGenics, Pfizer enter global research collaboration and license agreement for DART products

Boehringer Ingelheim and MacroGenics enter global antibody-based therapeutics alliance

AutoGenomics granted FDA 510(k) clearance for INFINITI CYP2C19 Assay

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

miRagen and CU enter agreement on miRNA therapeutics discovery and development

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News